Effect of combined VEGF<sub>165</sub>/ SDF-1 gene therapy on vascular remodeling and blood perfusion in cerebral ischemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27982773.
- Also identified by DOI 10.3171/2016.9.JNS161234.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
OBJECTIVE Therapeutic neovascularization is a promising strategy for treating patients after an ischemic stroke; however, single-factor therapy has limitations. Stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) proteins synergistically promote angiogenesis. In this study, the authors assessed the effect of combined gene therapy with VEGF<sub>165</sub> and SDF-1 in a rat model of cerebral infarction. METHODS An adenoviral vector expressing VEGF<sub>165</sub> and SDF-1 connected via an internal ribosome entry site was constructed (Ad- VEGF<sub>165</sub>-SDF-1). A rat model of middle cerebral artery occlusion (MCAO) was established; either Ad- VEGF<sub>165</sub>-SDF-1 or control adenovirus Ad- LacZ was stereotactically microinjected into the lateral ventricle of 80 rats 24 hours after MCAO. Coexpression and distribution of VEGF<sub>165</sub> and SDF-1 were examined by reverse-transcription polymerase chain reaction, Western blotting, and immunofluorescence. The neurological severity score of each rat was measured on Days 3, 7, 14, 21, and 28 after MCAO. Angiogenesis and vascular remodeling were evaluated via bromodeoxyuridine and CD34 immunofluorescence labeling. Relative cerebral infarction volumes were determined by T2-weighted MRI and triphenyltetrazolium chloride staining. Cerebral blood flow, relative cerebral blood volume, and relative mean transmit time were assessed using perfusion-weighted MRI. RESULTS The Ad- VEGF<sub>165</sub>-SDF-1 vector mediated coexpression of VEGF<sub>165</sub> and SDF-1 in multiple sites around the ischemic core, including the cortex, corpus striatum, and hippocampal granular layer. Coexpression of VEGF<sub>165</sub> and SDF-1 improved neural function, reduced cerebral infarction volume, increased microvascular density and promoted angiogenesis in the ischemic penumbra, and improved cerebral blood flow and perfusion. CONCLUSIONS Combined VEGF<sub>165</sub> and SDF-1 gene therapy represents a potential strategy for improving vascular remodeling and recovery of neural function after cerebral infarction.
Medical subject headings
- Brain Ischemia
- Cerebrovascular Circulation
- Chemokine CXCL12
- Genetic Therapy
- Vascular Endothelial Growth Factor A
- Vascular Remodeling